Noramco to manufacture CBD to be delivered via the eye

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Batke)
(Image: Getty/Batke)

Related tags CBD Cannabidiol Noramco Nemus Bioscience

Noramco partners with Nemus to produce an analogue of cannabidiol that possesses greater bioavailability, that could be used to treat diseases of the retina.

Nemus Bioscience secured the services of Noramco to manufacture and assist in the scale up process of its cannabidiol (CBD) analogue, cannabidiol-valine-hemisuccinate (CBDVHS).

Bill Grubb, chief innovation officer at Noramco, explained why the partnership was formed: “Noramco’s technical knowledge in cannabinoid process development and scale-up, as well as clinical manufacturing capabilities, were complementary to Nemus’ desire to bring novel, differentiated cannabinoid therapies to patients.”

He added that Nemus had been referred to work with Noramco by a ‘leading US university’ that specialises in cannabinoid research.

The analogue, itself, possesses greater bioavailability compared to CBD, according to results seen in initial animal studies by Nemus. The investigational compound was developed by the University of Mississippi, using amide ester bioengineering.

Nemus has licensed the technology to develop therapeutic options for diseases of the retina, such as macular degeneration and diabetic retinopathy. The greater bioavailability of the compound could allow it to penetrate into the posterior chamber of the eye, Nemus stated.

The aim is to scale up production of CBDVHS to conduct pre-clinical and clinical studies.

Josh Hoerner, MD of R&D and clinical solutions at Noramco, told us what this would entail, “There are a number of challenges with manufacturing a unique analogue of CBD. Some specific examples include taking a small-scale medicinal chemistry route and developing it into a robust and scalable manufacturing route, developing new analytical methods, and proving the stability of the new analogue.”

However, Hoerner outlined that Noramco had been able to address these challenges to produce a product suitable for parenteral drug delivery.

Grubb had previously told us​ that demand for CBD APIs is growing and he projected this would continue to grow over the next five years – pointing to potential compound annual growth rate of between 24% and 55%.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...